NeoGraph Analytics
PharmaceuticalsGlobal2026 – 2032

Ophthalmic Therapeutics Market Size, Share & Forecast 2026-2032

Four companies disclose $14.96bn of ophthalmic revenue, $12.85bn of it anti-VEGF - and the US branded intravitreal market shrank 15% in 2025. What that implies.

Revenue, 2026

$51.4B

Forecast, 2032

$66.0B

CAGR, 2026-2032

4.26%

Report Coverage

Global

Code: ophthalmic-therapeutics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Published estimates of this market agree on size to within 1.41x - $34.90 billion to $49.3 billion for 2025 - which is the narrowest spread in this research batch. That agreement is real and it is also beside the point, because the publishers who agree about the total are irreconcilable about what is in it, and in ophthalmology the structure is checkable brand by brand.

Two sources were read directly from their own pages. IMARC's drug-class taxonomy is anti-glaucoma, anti-infection, anti-inflammation, anti-allergy and others - anti-VEGF is not a listed class, which puts Eylea, Vabysmo, Lucentis and Beovu inside 'others' - and it states that anti-glaucoma is the largest class. Market Glass names anti-VEGF agents correctly as a class of its own, and then publishes a United States total of $10.0 billion for 2025.

Four companies disclose enough to test both claims. Regeneron's US Eylea and Eylea HD net sales were $4.4 billion in 2025, down 27%. Bayer, which holds the rest of the world, reported Eylea at EUR 3,110 million, down 5.9%. Roche reported Vabysmo at CHF 4,102 million, up about 12%. AbbVie's eye care lines sum to roughly $2.11 billion. That is $14.96 billion in total at the IRS 2025 yearly average rates, of which $12.85 billion is three anti-VEGF brands - before Lucentis, Beovu or any biosimilar. Novartis no longer breaks out its ophthalmology products at all, so the sum is a floor.

The Eylea franchise is split by geography between two disclosing companies, which hands over a measured US weighting: $4.4 billion US against $3.51 billion rest-of-world, so the United States is 55.6% of that brand. Apply it to the disclosed anti-VEGF total and US anti-VEGF revenue is about $7.14 billion - 71% of Market Glass's entire published US ophthalmic drugs market, leaving $2.9 billion for all US glaucoma, anti-infective, anti-allergy and dry-eye products and the whole over-the-counter artificial tears category that publisher says is in scope. And disclosed anti-VEGF revenue is 21 times AbbVie's branded glaucoma portfolio of roughly $608 million, which makes anti-glaucoma the largest class by prescription count and nowhere near it by revenue. Neither published structure survives.

What does survive is IMARC's total and, more importantly, its rate. Roche's pharmaceuticals head said the branded intravitreal injection market in the United States shrank 15% through 2025. Bayer guides its own franchise down 20% to 25% for 2026. Three of the five approved aflibercept biosimilars have not launched yet. Every growing number in the disclosed record - Eylea HD up 36%, Eylea 8 mg at 38% of Bayer's fourth quarter, Vabysmo taking share - is substitution inside a contracting class. 4.26% is the only published rate that does not require the largest class in ophthalmology to be growing.

02

Key Highlights

1

Published 2025 totals span only 1.41x, from $34.90 billion to $49.3 billion, while published CAGRs span 2.09x - the disagreement is about growth, not size

2

Four companies disclose $14.96 billion of ophthalmic revenue for 2025, $12.85 billion of it from three anti-VEGF brands, with Novartis absent because it no longer breaks its products out

3

The US is a measured 55.6% of the Eylea franchise, because Regeneron's US-only $4.4 billion and Bayer's rest-of-world $3.51 billion are two disclosed halves of one brand

4

Applying that share, three anti-VEGF brands would be 71% of Market Glass's entire published US ophthalmic drugs market of $10.0 billion

5

Disclosed anti-VEGF revenue is 21 times AbbVie's branded glaucoma portfolio of roughly $608 million, which refutes the claim that anti-glaucoma leads by revenue

6

Roche's pharmaceuticals head stated the US branded intravitreal injection market shrank 15% through 2025, while Vabysmo gained share within it

7

Three of the five approved aflibercept biosimilars launch in the fourth quarter of 2026 or later, so the 2025 declines understate the erosion still to come

03

Market Overview

Market Context

Ophthalmology is two businesses that share an organ. One is a high-volume, low-price topical business - glaucoma drops, antibiotic and steroid drops, antihistamines, artificial tears - dispensed through pharmacies, overwhelmingly generic, and counted in hundreds of millions of prescriptions. The other is a low-volume, high-price injectable business: anti-VEGF agents delivered into the vitreous by a retina specialist, reimbursed under medical benefit, counted in millions of injections. By prescription count the first dwarfs the second. By revenue the second dwarfs the first, and the gap is roughly twenty to one at the brand level. That split is why published class rankings in this market are unreliable. A total built from pharmacy dispensing data will rank glaucoma first because glaucoma is where the scripts are; a total built from brand revenue will rank anti-VEGF first because that is where the dollars are. One source read directly for this report does the former and says so; the other names anti-VEGF as a class and then publishes a US total too small to hold it. A reader needs to know which construction a figure came from, and neither publisher says. The structural event is biosimilar entry into the injectable half. Ranibizumab went first - Novartis's Lucentis fell 39% year on year in a single quarter of 2025 and is no longer disclosed - and aflibercept is going now, with five approved biosimilars, two launched and a published price of $1,445. The originators' response has been to extend the dosing interval: Eylea HD and Eylea 8 mg hold price by reducing injection frequency, and Vabysmo competes on the same axis. That is a defensible commercial strategy and it is not market growth. NeoGraph's bispecific-antibodies-market report covers Vabysmo from the format side; this report covers the class it is competing in.

Published estimates of this market agree unusually closely on size - $34.90 billion to $49.3 billion for 2025, only 1.41x - and are irreconcilable on structure. One source read directly does not list anti-VEGF as a drug class at all and says anti-glaucoma is the largest; another names anti-VEGF correctly and then publishes a United States total of $10.0 billion that three disclosed anti-VEGF brands would fill 71% of on their own. Four companies disclose $14.96 billion of ophthalmic revenue, $12.85 billion of it anti-VEGF, and every trajectory in that class is negative or substitutional: Roche's pharma chief said the US branded intravitreal market shrank 15% through 2025. On the only published rate consistent with that, this is a $51.40 billion market in 2026 reaching $66.02 billion by 2032 at 4.26%.

Market Stage

Mature

Adoption Level

Universal; growth constrained by biosimilar pricing rather than by uptake

Key Trends

Published 2025 totals span only 1.41x while published CAGRs span 2.09x - the disagreement has moved from size to growth, and the growth question is settled by disclosed brand revenueRoche's pharmaceuticals head stated the branded intravitreal injection market in the United States shrank by 15% through 2025, while Vabysmo gained share within itRegeneron's US Eylea franchise fell 27% to $4.4 billion in 2025; Bayer's rest-of-world Eylea fell 5.9% to EUR 3,110 million and is guided down 20% to 25% for 2026Growth inside the class is substitutional: Eylea HD rose 36% to $1.6 billion in the US while legacy Eylea fell, and the 8 mg presentation was about 38% of Bayer's Eylea by the fourth quarterFive aflibercept biosimilars are FDA-approved and three of them launch in the fourth quarter of 2026 or later, so the 2025 declines are the start of erosion rather than the endNovartis no longer breaks out Lucentis, Beovu or Xiidra in its full-year results, which is the clearest statement available of where the class that Lucentis created has goneDisclosed anti-VEGF revenue is 21 times the leading branded glaucoma portfolio, which refutes the claim that anti-glaucoma is the largest ophthalmic drug class by revenue
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 4.26%

Base Year (2026)

$51.4B

Forecast (2032)

$66.0B

CAGR (2026-2032)

4.26%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$51.40B
2027$53.59B
2028$55.87B
2029$58.25B
2030$60.73B
2031$63.32B
2032$66.02B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

The curve starts at $51.40 billion for 2026, derived by advancing IMARC's own published 2025 figure of $49.3 billion one year at IMARC's own stated 4.26% rate, and compounds at that rate to $66.02 billion by 2032. Intermediate years are interpolation. The implied rate between our endpoints is 4.26%, identical to the published one. We publish the lowest rate in the set deliberately, and the disclosed record is the reason. The largest class in this market by revenue contracted in its largest geography in 2025 - 15% on Roche's own account - and the originator holding the rest-of-world rights has guided its franchise down 20% to 25% for 2026. Three of the five approved aflibercept biosimilars have not launched yet. Against that, a whole-market rate of 7.6% or 8.9% would require the remaining classes to grow enough to absorb the decline and still deliver high single digits, in categories whose volume is generic and whose price per unit is a few dollars. It is worth noting which way the publishers themselves moved. IMARC cut its own forecast rate from 4.44% to 4.26% between editions - the only cross-edition revision in this batch that went in the direction the evidence went. Everywhere else in this research round, houses revised upward while the industries they were describing decelerated. The risk to this forecast is not that 4.26% is too high or too low in aggregate but that the aggregate hides a composition shift. The realistic path is a declining branded injectable line, a rising biosimilar line at a third to a half of the price, and steady low-single-digit growth in topical and over-the-counter volume - which can net to 4% while the revenue pool reorganises completely. Readers should treat the line as a trend and track the anti-VEGF brand disclosures quarter by quarter, because those are the only hard numbers in this market and they are all moving.

05

Market Dynamics

  • Ageing populations in every high-income market, which raises the prevalence of age-related macular degeneration, diabetic macular oedema and glaucoma simultaneously
  • Extended-interval anti-VEGF dosing - Eylea HD and Eylea 8 mg, Vabysmo's treat-and-extend label - which reduces injection burden and sustains branded volume against biosimilars
  • Diabetes prevalence driving diabetic macular oedema and diabetic retinopathy into treatment at younger ages than age-related disease
  • Emerging-market access expansion, where generic glaucoma and anti-infective drops are the volume and where the published forecasts locate most of their growth
  • A genuinely new dry-eye and ocular-surface category - with branded entrants outside the legacy cyclosporine franchises - that is not yet subject to generic erosion
06

Market Segmentation

By Type

  • Anti-VEGF intravitreal agents
  • Anti-glaucoma agents
  • Anti-inflammatory agents including corticosteroids and NSAIDs
  • Anti-infective agents
  • Anti-allergy agents
  • Dry eye and ocular surface therapies
  • Intravitreal implants and sustained-release delivery
  • Over-the-counter lubricants and artificial tears

By End User

  • Retina specialist practices and injection clinics
  • Hospital ophthalmology departments
  • Community ophthalmology and optometry practices
  • Hospital and retail pharmacies
  • Online pharmacies

By Application

  • Neovascular age-related macular degeneration
  • Diabetic macular oedema and diabetic retinopathy
  • Retinal vein occlusion
  • Glaucoma and ocular hypertension
  • Dry eye disease
  • Ocular infection, inflammation and uveitis
  • Allergic conjunctivitis
  • Myopia progression
07

Competitive Landscape

R

Regeneron Pharmaceuticals

United States

Holds the largest single disclosed US ophthalmic franchise, and the largest disclosed decline

Reported combined EYLEA HD and EYLEA US net sales of $4.4 billion for 2025, down 27%, of which EYLEA HD was $1.6 billion, up 36%. The two halves of that number are the market's structure in miniature: the new extended-interval presentation is growing fast and is cannibalising the original, while biosimilars take the base. Regeneron holds US rights only; Bayer holds the rest of the world. Market share is not disclosed.

B

Bayer AG

Germany

Holds Eylea outside the United States, and has guided its own decline

Reported Eylea sales of EUR 3,110 million for 2025 against EUR 3,306 million in 2024, down 5.9% as reported, attributing the fall to pricing pressure from biosimilar entry partly offset by volume on the 8 mg presentation, which was about 26% of Eylea sales for the year and roughly 38% in the fourth quarter. Bayer guides Eylea down 20% to 25% for 2026 - the originator's own statement of how much erosion is still ahead. Market share is not disclosed.

R

Roche Holding AG

Switzerland

The only company taking share in a contracting class

Reported Vabysmo sales of CHF 4,102 million for 2025, up about 12%, with the fourth quarter around 8% below analyst consensus. Roche's pharmaceuticals head attributed the shortfall to the United States, stating that the branded intravitreal injection market there shrank by 15% through 2025 while Vabysmo still gained share - the single most useful sentence anyone published about this market in 2025. Vabysmo is an anti-VEGF-A and anti-Ang-2 bispecific and is also covered in NeoGraph's bispecific-antibodies-market report. Market share is not disclosed.

A

AbbVie Inc.

United States

The largest non-retinal ophthalmic portfolio, and the reference point for glaucoma economics

Its FY2025 Form 10-K reports Ozurdex at $493 million, Other Eye Care at $1,009 million and separate lines for Lumigan/Ganfort and Alphagan/Combigan; summing the lines gives approximately $2.11 billion for 2025 against roughly $2.24 billion in 2024, which is our arithmetic rather than a reported total. Its branded glaucoma portfolio of roughly $608 million is the figure that refutes the claim that anti-glaucoma is the largest ophthalmic drug class by revenue - disclosed anti-VEGF revenue is 21 times larger. Market share is not disclosed.

N

Novartis AG

Switzerland

Created the class and no longer reports it

Lucentis made intravitreal anti-VEGF therapy a market. Novartis no longer breaks out Lucentis, Beovu or Xiidra in its full-year results, which means none clears the threshold for its top-brand table; the only figure located is Lucentis at $173 million in the second quarter of 2025, down 39% on generic competition. Novartis's ophthalmology revenue is therefore absent from the disclosed sum in this report, which is why that sum is described as a floor. Market share is not disclosed.

A

Amgen Inc.

United States

First aflibercept biosimilar to reach the US market

Launched Pavblu in October 2024, the first Eylea biosimilar in the United States, after the Federal Circuit declined to enjoin it, at roughly a 10% discount to the originator. One source states FDA has not designated it interchangeable, and sources conflict on that point. Amgen does not disclose Pavblu revenue separately, so the biosimilar side of this market is visible in the originators' declines rather than in the entrants' sales. Market share is not disclosed.

B

Biocon Biologics

India

Second aflibercept biosimilar launch, and the first public price point

Launched Yesafili in the United States in August 2026 at $1,445, with interchangeability resting on Phase 3 comparability data. That price is the clearest public marker of where anti-VEGF unit economics are heading, and it is the mechanism behind Bayer's 20% to 25% decline guidance. No disclosed Yesafili revenue and no market share.

S

Samsung Bioepis and Sandoz

South Korea and Switzerland

Approved but largely unlaunched aflibercept biosimilars

Opuviz, from Samsung Bioepis with Biogen, was approved in May 2024 with interchangeability; Enzeevu, from Sandoz, was approved in August 2024 with FDA provisionally determining interchangeability and a launch expected in the fourth quarter of 2026, alongside Formycon and Klinge's Ahzantive under litigation settlements. Three of the five approved aflibercept biosimilars therefore launch in late 2026 or later, which is why the 2025 declines understate the eventual erosion. No disclosed revenue and no market share.

08

Recent Developments

26
2026Regeneron Pharmaceuticals

Reported on 30 January 2026 that combined EYLEA HD and EYLEA US net sales fell 27% to $4.4 billion for 2025, while EYLEA HD alone rose 36% to $1.6 billion - growth and decline inside the same franchise.

26
2026Roche Holding AG

Reported Vabysmo at CHF 4,102 million for 2025, up about 12% but roughly 8% below consensus in the fourth quarter, with the company's pharmaceuticals head stating that the US branded intravitreal injection market shrank 15% through 2025.

26
2026Bayer AG

Reported Eylea at EUR 3,110 million for 2025, down 5.9%, with the 8 mg presentation at about 38% of Eylea sales in the fourth quarter, and guided Eylea sales down 20% to 25% for 2026 on biosimilar pricing pressure.

26
2026Biocon Biologics

Launched Yesafili in the United States in August 2026 at a price of $1,445, becoming the second aflibercept biosimilar on the US market.

26
2026IMARC Group

Updated its ophthalmic drugs market report on 26 June 2026, cutting its own forecast CAGR from 4.44% to 4.26% - the only cross-edition revision in this research batch that moved in the direction the disclosed record actually went.

24
2024Amgen

Launched Pavblu in October 2024 as the first Eylea biosimilar on the US market, at roughly a 10% discount, after the Federal Circuit denied Regeneron's request to enjoin the launch.

09

Regulatory Landscape

The US biosimilar pathway under section 351(k) of the Public Health Service Act, under which five aflibercept biosimilars have been approved and which governs whether a product is designated interchangeable and therefore substitutable at the pharmacy or buy-and-bill levelFDA interchangeability determination, which sources report inconsistently for Pavblu and Enzeevu and which materially changes substitution rates - the designations should be checked against FDA's Purple Book rather than trade coveragePatent and exclusivity litigation around aflibercept, which has determined launch timing more than approval has: Pavblu launched in October 2024 only after the Federal Circuit declined to enjoin it, while Ahzantive and Enzeevu launch in the fourth quarter of 2026 under settlementsFDA label extensions that sustain branded volume against biosimilars, including EYLEA HD approval for retinal vein occlusion with dosing up to every eight weeks and an every-four-week option across approved indicationsNational pricing and reimbursement regimes for intravitreal injections, which Bayer cited by name - Canada, the United Kingdom and Japan - as the source of the price declines in its 2025 Eylea revenue
10

Research Methodology

Primary research

  • No primary interviews were conducted for this edition. The report rests on company filings and earnings releases, publisher pages read directly, and regulatory and legal-practice reporting on biosimilar status, and is labelled as such rather than implying fieldwork that did not occur.

Secondary research

  • Regeneron Pharmaceuticals fourth quarter and full year 2025 results, released 30 January 2026: US EYLEA HD and EYLEA net sales $4.4 billion, down 27%; EYLEA HD $1.6 billion, up 36%
  • Bayer AG Annual Report 2025 and FY2025 investor call of 4 March 2026: Eylea EUR 3,110 million against EUR 3,306 million, down 5.9% reported, with 8 mg at about 38% of Q4 sales and 2026 guidance of minus 20% to minus 25%
  • Roche Holding AG full year 2025 results: Vabysmo CHF 4,102 million, up about 12%, with the statement that the US branded intravitreal injection market shrank 15% through 2025
  • AbbVie Inc. Form 10-K for the year ended 31 December 2025: Ozurdex $493 million, Other Eye Care $1,009 million, plus Lumigan/Ganfort and Alphagan/Combigan lines
  • Novartis AG full year 2025 results (Form 6-K): Lucentis, Beovu and Xiidra not separately disclosed; Lucentis $173 million in Q2 2025, down 39%
  • IMARC Group, Ophthalmic Drugs Market (SR112026A5287), last updated 26 June 2026: $49.3 billion for 2025 to $72.6 billion by 2034 at 4.26%
  • Market Glass, Inc., Ophthalmic Drugs - Global Strategic Business Report (478 pages, ID 5985637, October 2026): $36.7 billion for 2025 to $61.1 billion by 2032 at 7.6%, with the United States at $10.0 billion in 2025
  • FDA approval and US launch record for the five aflibercept biosimilars - Pavblu, Opuviz, Ahzantive, Enzeevu and Yesafili - including Yesafili's August 2026 launch price of $1,445
  • Internal Revenue Service yearly average currency exchange rates for 2025, EUR 0.886 and CHF 0.831 per US dollar, used for every conversion in this report
  • NeoGraph Analytics, Bispecific Antibodies Market, which covers Vabysmo in its capacity as a bispecific and defines the overlap declared in this report

Validation: The headline figures are IMARC Group's own published 2025 value of $49.3 billion and its own stated 4.26% rate; the 2026 base and the 2032 endpoint are interpolation on that published rate, not separate observations. That series was chosen because its rate is the only published one consistent with the disclosed trajectory of the market's largest class, and because its total survives the disclosure test. The grounding sums the four disclosed ophthalmic revenue lines at the IRS 2025 yearly average rates of EUR 0.886 and CHF 0.831: Regeneron's US Eylea franchise $4,400 million, Bayer's rest-of-world Eylea EUR 3,110 million or $3,510 million, Roche's Vabysmo CHF 4,102 million or $4,936 million, and AbbVie's eye care portfolio at approximately $2,110 million, which is our own sum of four Form 10-K product lines rather than a reported total. The sum is $14,956 million, of which $12,846 million is the three anti-VEGF brands. That is 30.3% of IMARC's total and 40.8% of Market Glass's, both survivable, so a second test discriminates: the United States is a measured 55.6% of the Eylea franchise, since Regeneron's US-only $4,400 million and Bayer's rest-of-world $3,510 million are the two disclosed halves of one brand. Applying that share to the disclosed anti-VEGF total gives roughly $7,142 million of US anti-VEGF revenue, which is 71.4% of Market Glass's own published US ophthalmic drugs total of $10.0 billion, leaving about $2.9 billion for every US glaucoma, anti-infective, anti-inflammatory, anti-allergy and dry-eye product and the whole over-the-counter artificial tears category that publisher says is in scope. A third test addresses structure rather than size: disclosed anti-VEGF revenue of $12,846 million is 21.1 times AbbVie's branded glaucoma portfolio of roughly $608 million, which makes the claim that anti-glaucoma is the largest drug class untenable by revenue, however true it is by prescription count. We therefore publish IMARC's total and rate and none of its structural rankings. These are scope, structure and plausibility tests, not market estimates. AbbVie's eye-care total is our arithmetic from 10-K lines read via a search summary. The 55.6% US share is measured for Eylea and assumed for the rest of the class. Novartis's ophthalmology revenue is absent from the sum entirely, so the disclosed total is a floor. Roche's growth rate and the US intravitreal contraction figure were read from trade coverage rather than Roche's own release. And dividing company revenue into a published market total compares differently constructed numbers. No vendor share, regional split or country split is published anywhere in this report.

11

Strategic Takeaways

Ask how a class ranking was constructed before using it

pharmacy-dispensing data puts glaucoma first, brand revenue puts anti-VEGF first by roughly twenty to one, and publishers do not say which they did

Use the Eylea franchise as the US weighting benchmark - $4.4 billion US against $3.51 billion rest-of-world is a measured 55.6%, not an assumption

Reject any US ophthalmic drugs total that three anti-VEGF brands would fill most of; $10.0 billion for 2025 does not accommodate the class plus the generics and OTC the same scope claims

Treat anti-VEGF growth as substitution, not expansion

Eylea HD up 36% and Eylea 8 mg at 38% of Bayer's fourth quarter are the same patients on fewer injections

Expect further erosion rather than a trough - three of five approved aflibercept biosimilars launch in late 2026 or later, and Bayer has guided minus 20% to minus 25% for its own franchise

Read Novartis's silence as information

a company that no longer breaks out the product which created this class is telling you where the class went

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.